A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin

AIMS: To investigate the efficacy, safety and tolerability of sitagliptin 50 mg once daily added to ipragliflozin 50 mg once daily monotherapy in Japanese patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Japanese patients with T2D and glycated haemoglobin (HbA1c) 7.0% to 10.0% while treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Seino, Yutaka, Kaku, Kohei, Kadowaki, Takashi, Okamoto, Taro, Sato, Asako, Shirakawa, Masayoshi, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248366/
https://www.ncbi.nlm.nih.gov/pubmed/33565686
http://dx.doi.org/10.1111/dom.14346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248366/
https://www.ncbi.nlm.nih.gov/pubmed/33565686
http://dx.doi.org/10.1111/dom.14346

Ejemplares similares